Probiotics in nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and cirrhosis

Journal of Clinical Gastroenterology

Volumn 49, Issue , 2015, Pages S28-S32

  Qamar, Amir A ^a  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Cirrhosis; Intestinal microbiota; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Probiotics

Indexed keywords

PROBIOTIC AGENT;

ARTICLE; BACTERIAL PERITONITIS; BACTERIAL TRANSLOCATION; BACTERIUM ADHERENCE; CONTROLLED CLINICAL TRIAL (TOPIC); ESOPHAGUS VARICES; FATTY LIVER; HEPATIC ENCEPHALOPATHY; HUMAN; INTESTINE FLORA; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); COMPLICATION; INTESTINE; METABOLISM; MICROBIOLOGY; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PERMEABILITY;

BACTERIAL TRANSLOCATION; GASTROINTESTINAL MICROBIOME; HEPATIC ENCEPHALOPATHY; HUMANS; HYPERTENSION, PORTAL; INTESTINES; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PERMEABILITY; PROBIOTICS;

EID: 84944240105     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000347     Document Type: Article

References (43)

1. Vleggaar FP, Monkelbaan JF, van Erpecum KJ. Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur J Gastroenterol Hepatol. 2008;20:688-692.
2. Rayes N, Seehofer D, Theruvath T, et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation-a randomized, double-blind trial. Am J Transplant. 2005;5:125-130.
3. Eguchi S, Takatsuki M, Hidaka M, et al. Perioperative synbiotic treatment to prevent infectious complications in patients after elective living donor liver transplantation: a prospective randomized study. Am J Surg. 2011;201:498-502.
4. Aller R, De Luis DA, Izaola O, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011;15:1090-1095.
5. Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL# 3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005;39:540-543.
6. Solga SF, Buckley G, Clark JM, et al. The effect of a probiotic on hepatic steatosis. J Clin Gastroenterol. 2008;42:1117-1119.
7. Vajro P, Mandato C, Licenziati MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011;52:740-743.
8. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308:1635-1638.
9. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003;361:512-519.
10. Sabate JM, Jouet P, Harnois F, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg. 2008;18:371-377.
11. Lee YK. Effects of diet on gut microbiota profile and the implications for health and disease. Biosci Microbiota Food Health. 2013;32:1-12.
12. Backhed F, Manchester JK, Semenkovich CF, et al. Mechanisms of underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci. 2007;104:979-984.
13. Cope K, Risby T, Diehl AM. Increased gastrointestinal ethanol production and obese mice: implications for fatty liver disease pathogenesis. Gastroenterology. 2000;199:1340-1347.
14. Salaspuro M. Bacteriocolonic pathway for ethanol oxidation: characteristics and implications. Ann Med. 1996;28:195-200.
15. Spencer MD, Hamp TJ, Reid RW, et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology. 2011;140:976-986.
16. Sayin SI, Wahlstrom A, Felin J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-betamuricholic acid, a natural occurring FXR antagonist. Cell Metab. 2013;17:225-235.
17. Dumas ME, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin resistant mice. Proc Natl Acad Sci USA. 2006;103:12511-12516.
18. Alisi A, Manco M, Devito R, et al. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children: 1877-1887. J Pediatr Gastroenterol Nutr. 2010;50:645-649.
19. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877-1887.
20. Haller D, Bode C, Hammes WP, et al. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut. 2000;47:79-87.
21. Helgeland L, Vaage JT, Rolstad B, et al. Microbial colonization influences composition and T-cell receptor V beta repertoire of intraepithelial lymphocytes in rat intestine. Immunology. 1996;89:494-501.
22. Macfarlane GT, Cummings JH. Probiotics, infection and immunity. Curr Opin Infect Dis. 2002;15:501-506.
23. Luyer MD, Buurman WA, Hadfoune M, et al. Strain specific effects of probiotics on gut barrier integrity following hemorrhagic shock. Infect Immun. 2005;73:3686-3692.
24. Zareie M, Johnson-Henry K, Jury J, et al. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats follow chronic psychological stress. Gut. 2006;55:1553-1560.
25. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121:580-591.
26. Resta Lenert S, Barret K. Live probiotics protect intestinal epithelial cells form the effects of infection with enteroinvasive Escherichia coli. (EIEC) Gut. 2003;52:988-997.
27. Menningen R, Nolte K, Rijcken E, et al. Probiotic mixture VSL# 3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol. 2009;296:G1140-G1149.
28. Heinemann C, van Hylckama Vlieg JE, Janssen DB, et al. Purification and characterization of a surface-binding protein from Lactobacillus fermentum RC-14 that inhibits adhesion of Enterococcus faecalis 1131. FEMS Microbiol Lett. 2000;190:177-180.
29. Herias MV, Hessle C, Telemo E, et al. Immunomodulatory effects of Lactobacillus plantarium colonizing the intestine of gnotobiotic rats. Clin Exp Immunol. 1999;116:283-290.
30. Wai-Sun Wong V, Lai-Hung Wong G, Mei-Ling Chim A, et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol. 2013;12:256-262.
31. Malaguarnera M, Vacane M, Antic T, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012;57:545-553.
32. Campillo B, Pernet P, Bories PN, et al. Intestinal permeability and liver cirrhosis: relationship with severe septic complications. Eur J Gastroenterol Hepatol. 1999;11:755-759.
33. Thalheimer U, Triantos CK, Samonakis DN, et al. Infection, coagulation and variceal bleeding cirrhosis. Gut. 2005;54:556-563.
34. Rincon D, Vaquero J, Hernando A, et al. Oral probiotic VSL# 3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. Liver Int. 2014;34:1504-1512.
35. Husova L, Lata J, Husa P, et al. Bacterial infection and acute bleeding from upper gastrointestinal tract in patients with liver cirrhosis. Hepatogastroenterology. 2005;52:188-1490.
36. Bajaj JS, Hylemon PB, Younossi Y. The intestinal microbiota and liver disease. Am J Gastroenterol Suppl. 2012;1:9-14.
37. Dhiman RK, Rana B, Agrawal S, et al. Probiotic VSL# 3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology. 2014;147:1327-1337.
38. Jayakumar S, Carbonneau M, Hotte N, et al. VSL# 3 probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis. Liver Int. 2013;33:1470-1477.
39. Gupta N, Kumar A, Sharma P, et al. Effects of the adjunctive probiotic VSL# 3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. Liver Int. 2013;33:1148-1157.
40. Pande C, Kumar A, Sarin SK. Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo controlled randomized trial. Eur J Gastroenterol. 2012;24:831-839.
41. Mittal VV, Sharma BC, Sharma P, et al. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2011;23:725-732.
42. Agrawal A, Sharma BC, Sharma P, et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an openlabel randomized controlled trial of lactulose, probiotics and no therapy. Am J Gastroenterol. 2012;107:1043-1050.
43. Shukla S, Shukla A, Mehboob S, et al. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment Pharmacol Ther. 2011;33:662-671.